Zhejiang Medicine (SHA:600216) plans to spin off its subsidiary, Xinma Biopharmaceutical, for listing on the Hong Kong Stock Exchange, according to a Shanghai bourse filing on Saturday.
The Chinese drugmaker's shares dropped less than 4% on Monday.
Related Articles
Asia
Yuzhou Group Logs 482 Million Yuan in March Contracted Sales
Yuzhou Group (HKG:1628) recorded contracted sales of 482 million yuan in March, with a sales area of 37,351 square meters, according to a Friday Hong Kong bourse filing.The property company's average selling price stood at approximately 12,907 yuan per square meter for the month.In the first quarter of 2026, the accumulated sales amount was 1.37 billion yuan, with a sales area of 108,232 square meters and an average selling price of 12,700 yuan per square meter.
$HKG:1628
Asia
Alco's Co-Chairs Steps Down; Successors Named
Alco (HKG:0328) said co-chairpersons Liao Liping and Tian Yi have resigned effective Friday to devote more time to their personal endeavors, according to a same-day Hong Kong bourse filing.The consumer electronics company, on the same day, named Pan Ying as its new chair.Pan has served as the CEO of Shengjun Capital since March 2021.
$HKG:0328
Asia
Kong Sun's Electricity Output Declines in Q1
Kong Sun's (HKG:0295) solar power plants generated around 58,204 megawatt-hours of electricity in the first quarter of 2026, down from 73,664 megawatt-hours a year prior, according to a Friday Hong Kong bourse filing.As of March 31, the electricity services provider's total installed capacity stood at 300 megawatts.
$HKG:0295